New heart valve replacement could offer hope for severe leakage
NCT ID NCT06611579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new device called the inQB8 MonarQ system, which replaces the tricuspid valve using a thin tube (catheter) instead of open-heart surgery. It includes 50 people with severe tricuspid regurgitation, a condition where the valve leaks. The goal is to see if the device is safe and can reduce the leakage, improve heart function, and enhance quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inQB8 MonarQ Transcatheter Tricuspid Valve Replacement System (a device placed through a catheter to replace the tricuspid valve)
What this could lead to
If successful, this could offer a less invasive treatment option for people with severe tricuspid regurgitation, potentially improving heart function and daily life.
What could go wrong
This is an early study with only 50 participants, so results may not apply to everyone. The procedure carries risks like any heart device implant, and long-term benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICUSPID VALVE REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Sint-Jan Brugge AV
RECRUITINGBruges, 8000, Belgium
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Baylor Heart Hospital
RECRUITINGPlano, Texas, 75093, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Los Robles Hosptial and Medical Center
RECRUITINGThousand Oaks, California, 91360, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
North Shore University Hospital
RECRUITINGManhasset, New York, 11030, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Penn Presbyterian Medical Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Piedmont Atlanta Hospital
RECRUITINGAtlanta, Georgia, 30309, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Michael's Hospital
RECRUITINGToronto, Ontario, M5B1W8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact